Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1R206H Fibrodysplasia Ossificans Progressiva (FOP) Mutation

Salin A. Chakkalakal, Kenta Uchibe, Michael R. Convente, Deyu Zhang, Aris N. Economides, Frederick S. Kaplan, Maurizio Pacifici, Masahiro Iwamoto, Eileen M. Shore

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable genetic disorder of progressive extraskeletal ossification, is the most disabling form of heterotopic ossification (HO) in humans and causes skeletal deformities, movement impairment, and premature death. Most FOP patients carry an activating mutation in a bone morphogenetic protein (BMP) type I receptor gene, ACVR1R206H, that promotes ectopic chondrogenesis and osteogenesis and, in turn, HO. We showed previously that the retinoic acid receptor γ (RARγ) agonist palovarotene effectively inhibited HO in injury-induced and genetic mouse models of the disease. Here we report that the drug additionally prevents spontaneous HO, using a novel conditional-on knock-in mouse line carrying the human ACVR1R206H mutation for classic FOP. In addition, palovarotene restored long bone growth, maintained growth plate function, and protected growing mutant neonates when given to lactating mothers. Importantly, palovarotene maintained joint, limb, and body motion, providing clear evidence for its encompassing therapeutic potential as a treatment for FOP.

Original languageEnglish
Pages (from-to)1666-1675
Number of pages10
JournalJournal of Bone and Mineral Research
Volume31
Issue number9
DOIs
Publication statusPublished - Sep 1 2016
Externally publishedYes

Fingerprint

Palovarotene
Myositis Ossificans
Heterotopic Ossification
Extremities
Mutation
Growth
Osteogenesis
Type I Bone Morphogenetic Protein Receptors
Chondrogenesis
Inborn Genetic Diseases
Retinoic Acid Receptors
Premature Mortality
Growth Plate
Bone Development
Genetic Models
Joints
Mothers
Newborn Infant
Wounds and Injuries
Therapeutics

Keywords

  • ACVR1
  • FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)
  • HETEROTOPIC OSSIFICATION
  • PALOVAROTENE
  • RETINOIC ACID RECEPTOR (RAR)

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Medicine(all)
  • Orthopedics and Sports Medicine

Cite this

Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1R206H Fibrodysplasia Ossificans Progressiva (FOP) Mutation. / Chakkalakal, Salin A.; Uchibe, Kenta; Convente, Michael R.; Zhang, Deyu; Economides, Aris N.; Kaplan, Frederick S.; Pacifici, Maurizio; Iwamoto, Masahiro; Shore, Eileen M.

In: Journal of Bone and Mineral Research, Vol. 31, No. 9, 01.09.2016, p. 1666-1675.

Research output: Contribution to journalArticle

Chakkalakal, Salin A. ; Uchibe, Kenta ; Convente, Michael R. ; Zhang, Deyu ; Economides, Aris N. ; Kaplan, Frederick S. ; Pacifici, Maurizio ; Iwamoto, Masahiro ; Shore, Eileen M. / Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1R206H Fibrodysplasia Ossificans Progressiva (FOP) Mutation. In: Journal of Bone and Mineral Research. 2016 ; Vol. 31, No. 9. pp. 1666-1675.
@article{1e1a96a74d90423588ceed7368758814,
title = "Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1R206H Fibrodysplasia Ossificans Progressiva (FOP) Mutation",
abstract = "Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable genetic disorder of progressive extraskeletal ossification, is the most disabling form of heterotopic ossification (HO) in humans and causes skeletal deformities, movement impairment, and premature death. Most FOP patients carry an activating mutation in a bone morphogenetic protein (BMP) type I receptor gene, ACVR1R206H, that promotes ectopic chondrogenesis and osteogenesis and, in turn, HO. We showed previously that the retinoic acid receptor γ (RARγ) agonist palovarotene effectively inhibited HO in injury-induced and genetic mouse models of the disease. Here we report that the drug additionally prevents spontaneous HO, using a novel conditional-on knock-in mouse line carrying the human ACVR1R206H mutation for classic FOP. In addition, palovarotene restored long bone growth, maintained growth plate function, and protected growing mutant neonates when given to lactating mothers. Importantly, palovarotene maintained joint, limb, and body motion, providing clear evidence for its encompassing therapeutic potential as a treatment for FOP.",
keywords = "ACVR1, FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP), HETEROTOPIC OSSIFICATION, PALOVAROTENE, RETINOIC ACID RECEPTOR (RAR)",
author = "Chakkalakal, {Salin A.} and Kenta Uchibe and Convente, {Michael R.} and Deyu Zhang and Economides, {Aris N.} and Kaplan, {Frederick S.} and Maurizio Pacifici and Masahiro Iwamoto and Shore, {Eileen M.}",
year = "2016",
month = "9",
day = "1",
doi = "10.1002/jbmr.2820",
language = "English",
volume = "31",
pages = "1666--1675",
journal = "Journal of Bone and Mineral Research",
issn = "0884-0431",
publisher = "Wiley-Blackwell",
number = "9",

}

TY - JOUR

T1 - Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1R206H Fibrodysplasia Ossificans Progressiva (FOP) Mutation

AU - Chakkalakal, Salin A.

AU - Uchibe, Kenta

AU - Convente, Michael R.

AU - Zhang, Deyu

AU - Economides, Aris N.

AU - Kaplan, Frederick S.

AU - Pacifici, Maurizio

AU - Iwamoto, Masahiro

AU - Shore, Eileen M.

PY - 2016/9/1

Y1 - 2016/9/1

N2 - Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable genetic disorder of progressive extraskeletal ossification, is the most disabling form of heterotopic ossification (HO) in humans and causes skeletal deformities, movement impairment, and premature death. Most FOP patients carry an activating mutation in a bone morphogenetic protein (BMP) type I receptor gene, ACVR1R206H, that promotes ectopic chondrogenesis and osteogenesis and, in turn, HO. We showed previously that the retinoic acid receptor γ (RARγ) agonist palovarotene effectively inhibited HO in injury-induced and genetic mouse models of the disease. Here we report that the drug additionally prevents spontaneous HO, using a novel conditional-on knock-in mouse line carrying the human ACVR1R206H mutation for classic FOP. In addition, palovarotene restored long bone growth, maintained growth plate function, and protected growing mutant neonates when given to lactating mothers. Importantly, palovarotene maintained joint, limb, and body motion, providing clear evidence for its encompassing therapeutic potential as a treatment for FOP.

AB - Fibrodysplasia ossificans progressiva (FOP), a rare and as yet untreatable genetic disorder of progressive extraskeletal ossification, is the most disabling form of heterotopic ossification (HO) in humans and causes skeletal deformities, movement impairment, and premature death. Most FOP patients carry an activating mutation in a bone morphogenetic protein (BMP) type I receptor gene, ACVR1R206H, that promotes ectopic chondrogenesis and osteogenesis and, in turn, HO. We showed previously that the retinoic acid receptor γ (RARγ) agonist palovarotene effectively inhibited HO in injury-induced and genetic mouse models of the disease. Here we report that the drug additionally prevents spontaneous HO, using a novel conditional-on knock-in mouse line carrying the human ACVR1R206H mutation for classic FOP. In addition, palovarotene restored long bone growth, maintained growth plate function, and protected growing mutant neonates when given to lactating mothers. Importantly, palovarotene maintained joint, limb, and body motion, providing clear evidence for its encompassing therapeutic potential as a treatment for FOP.

KW - ACVR1

KW - FIBRODYSPLASIA OSSIFICANS PROGRESSIVA (FOP)

KW - HETEROTOPIC OSSIFICATION

KW - PALOVAROTENE

KW - RETINOIC ACID RECEPTOR (RAR)

UR - http://www.scopus.com/inward/record.url?scp=84985041077&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84985041077&partnerID=8YFLogxK

U2 - 10.1002/jbmr.2820

DO - 10.1002/jbmr.2820

M3 - Article

VL - 31

SP - 1666

EP - 1675

JO - Journal of Bone and Mineral Research

JF - Journal of Bone and Mineral Research

SN - 0884-0431

IS - 9

ER -